Emma Proud
Associate Manager, Value & Evidence
Expertise:
Emma joined the Value & Evidence team at EVERSANA in 2023 as a Research Associate.
During her time at EVERSANA, Emma has contributed to systematic and targeted literature reviews, manuscript development, economic modelling, and Canadian HTA submissions. She has experience across a diverse range of therapeutic areas including inflammatory disorders, rare disease, oncology, and medical devices.
Emma holds an Honours BSc from the University of Guelph, where she majored in biological science and minored in neuroscience, as well as an MSc in neuroscience from Western University. Her thesis examined the impact of prenatal nicotine exposure on the development of mood and anxiety disorders using cerebral organoids. She is a Canadian Graduate Scholar and was awarded a scholarship from the Natural Sciences and Engineering Research Council of Canada (NSERC) in support of her master’s research.
Articles by Emma Proud
Comparing CDK4/6 Inhibitors in Real-World Practice: What the Evidence Reveals
Palbociclib, ribociclib, and abemaciclib, the three approved CDK4/6 inhibitors, are established first-line treatment options for HR+/HER2− advanced or metastatic breast cancer (a/mBC). Yet no randomized, head-to-head trial has compared the three agents directly. In the absence of head-to-head randomized trials, clinicians, payers, and health technology assessment (HTA) bodies increasingly rely on real-world evidence (RWE) to […]